Scarica l'app Stockscreener
235.00
1.12%
2.70
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$232.30
Aprire:
$235.09
Volume 24 ore:
25,966
Relative Volume:
0.12
Capitalizzazione di mercato:
$4.71B
Reddito:
$268.09M
Utile/perdita netta:
$124.45M
Rapporto P/E:
40.28
EPS:
5.8347
Flusso di cassa netto:
$38.05M
1 W Prestazione:
+4.47%
1M Prestazione:
+15.37%
6M Prestazione:
+12.81%
1 anno Prestazione:
+127.35%
Intervallo 1D:
$231.85
$236.00
Intervallo di 1 settimana:
$220.06
$236.22
Portata 52W:
$98.89
$247.38
Ligand Pharmaceuticals Inc Stock (LGND) Company Profile
Nome
Ligand Pharmaceuticals Inc
Settore
Industria
Telefono
858-550-7500
Indirizzo
3911 SORRENTO VALLEY BLVD, SAN DIEGO, CA
Compare LGND vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
LGND
Ligand Pharmaceuticals Inc
|
235.20 | 4.65B | 268.09M | 124.45M | 38.05M | 5.8347 |
VRTX
Vertex Pharmaceuticals Inc
|
428.60 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
718.43 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
811.45 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
304.43 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
313.57 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Ligand Pharmaceuticals Inc Stock (LGND) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-11 | Iniziato | BofA Securities | Buy |
| 2025-12-09 | Iniziato | Citigroup | Buy |
| 2025-04-10 | Iniziato | Stifel | Buy |
| 2024-10-03 | Iniziato | Oppenheimer | Outperform |
| 2024-07-30 | Iniziato | RBC Capital Mkts | Outperform |
| 2021-04-14 | Ripresa | Stephens | Overweight |
| 2021-02-04 | Reiterato | H.C. Wainwright | Buy |
| 2020-10-06 | Iniziato | Barclays | Overweight |
| 2020-03-24 | Downgrade | Argus | Buy → Hold |
| 2020-03-10 | Iniziato | Guggenheim | Neutral |
| 2020-02-06 | Iniziato | The Benchmark Company | Buy |
| 2019-09-19 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2019-06-11 | Iniziato | Barclays | Equal Weight |
| 2019-05-03 | Reiterato | H.C. Wainwright | Buy |
| 2019-03-06 | Reiterato | H.C. Wainwright | Buy |
| 2018-10-29 | Aggiornamento | ROTH Capital | Neutral → Buy |
| 2018-10-02 | Reiterato | H.C. Wainwright | Buy |
| 2018-09-11 | Reiterato | Argus | Buy |
| 2018-08-17 | Iniziato | Goldman | Neutral |
| 2018-08-08 | Downgrade | ROTH Capital | Buy → Neutral |
| 2018-06-21 | Iniziato | Argus | Buy |
| 2017-12-27 | Reiterato | H.C. Wainwright | Buy |
| 2017-09-05 | Ripresa | H.C. Wainwright | Buy |
| 2016-10-05 | Reiterato | H.C. Wainwright | Buy |
| 2016-08-05 | Downgrade | Deutsche Bank | Hold → Sell |
| 2016-03-11 | Iniziato | Sidoti | Buy |
| 2016-03-03 | Iniziato | H.C. Wainwright | Buy |
Mostra tutto
Ligand Pharmaceuticals Inc Borsa (LGND) Ultime notizie
Ligand CEO joins Palvella chief at May 6 investor fireside chat - Stock Titan
Ligand to Participate in May Investor Conferences - Yahoo Finance
Ligand to buy XOMA Royalty for $39/share - MSN
Ligand Pharmaceuticals CLO Andrew Reardon sells $1.16m in stock - Investing.com
CLO Andrew Reardon nets 5,000-share sale at Ligand (NASDAQ: LGND) - Stock Titan
Villere St Denis Liquidates $18 Million Euronet Worldwide Stake, According to Recent SEC Filing - The Motley Fool
MSN Money - MSN
LGND PE Ratio & Valuation, Is LGND Overvalued - Intellectia AI
Ligand Pharmaceuticals Incorporated $LGND Shares Sold by Kornitzer Capital Management Inc. KS - MarketBeat
XOMA (XOMA) holders offered $39 cash plus CVRs in Ligand buyout - Stock Titan
Ligand Pharmaceuticals Launches Takeover Plan at XOMA Royalty Corporation with 47.0% Stake - TradingView
Ligand Pharma Ends TR‑Beta License With Viking Therapeutics - The Globe and Mail
LGND (NASDAQ) Rule 144 notice lists 467 common shares and dated sales - Stock Titan
Vanguard reports 5.56% stake in Ligand Pharmaceuticals (NASDAQ: LGND) - Stock Titan
Vanguard Capital Management files Schedule 13G on Ligand (LGND) showing 5% stake - Stock Titan
HC Wainwright Brokers Increase Earnings Estimates for LGND - MarketBeat
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Ligand bets on royalty growth with XOMA buyout worth over $700 million - MSN
[8-K] LIGAND PHARMACEUTICALS INC Reports Material Event - Stock Titan
LGND Maintained by HC Wainwright & Co. -- Price Target Raised to $289 - GuruFocus
HC Wainwright Issues Positive Forecast for Ligand Pharmaceuticals (NASDAQ:LGND) Stock Price - MarketBeat
Ligand Pharmaceuticals is buying Xoma for nearly $740 million - MSN
Ligand Pharmaceuticals (NASDAQ:LGND) Shares Gap DownHere's Why - MarketBeat
LGND: XOMA Buy Adds 100+ Assets - Smartkarma
Moody Aldrich Partners LLC Has $3.70 Million Stock Holdings in Ligand Pharmaceuticals Incorporated $LGND - MarketBeat
Ligand Pharmaceuticals to buy XOMA Royalty in $740M all-cash deal: WSJ - MSN
LGND Maintained by RBC Capital -- Price Target Raised to $252 - GuruFocus
Ligand to acquire XOMA Royalty - The Pharma Letter
Royal Bank Of Canada Issues Positive Forecast for Ligand Pharmaceuticals (NASDAQ:LGND) Stock Price - MarketBeat
Ligand Pharmaceuticals And 2 Other Stocks That May Be Trading At An Estimated Discount - Yahoo Finance
RBC Raises Price Target on Ligand Pharmaceuticals to $252 From $235, Keeps Outperform Rating - Moomoo
RBC Capital raises Ligand Pharma stock price target on XOMA deal - Investing.com Canada
Ligand Pharmaceuticals to Buy XOMA Royalty for $39/Share, Lifts 2026 Guidance and EPS Outlook - Yahoo Finance
Why Ligand's $739M Xoma buy matters for growth - Axios
BofA raises Ligand Pharma stock price target on XOMA acquisition - Investing.com
Stifel raises Ligand Pharma stock price target on XOMA acquisition - Investing.com UK
BofA raises Ligand Pharma stock price target on XOMA acquisition By Investing.com - Investing.com Canada
Stifel raises Ligand Pharma stock price target on XOMA acquisition By Investing.com - Investing.com India
Ligand Pharmaceuticals (NASDAQ:LGND) Updates FY 2026 Earnings Guidance - MarketBeat
Ligand Pharma to acquire fellow biotech royalty rights buyer XOMA for $739 million - 104.1 WIKY
Ligand Bets On Royalty Growth With XOMA Buyout Worth Over $700 Million - Benzinga
Ligand Pharmaceuticals Incorporated entered into a definitive agreement to acquire XOMA Royalty Corporation for approximately $470 million from BVF Partners L.P. and others. - marketscreener.com
Ligand Pharmaceuticals Acquires Zoma for $740 Million - GuruFocus
Ligand Pharmaceuticals (LGND) to Acquire Xoma Royalty for $39 pe - GuruFocus
Ligand Pharmaceuticals stock hits 52-week high at 240.25 USD By Investing.com - Investing.com Canada
Ligand Pharmaceuticals to Acquire XOMA Royalty for $39 Per Share Plus CVRs - TradingView
Ligand strikes $739M deal for Xoma Royalty - Axios
Ligand Pharmaceuticals to Acquire Xoma Royalty for 739 Million Dollars - HarianBasis.co
Ligand (Nasdaq: LGND) to acquire XOMA Royalty in $739M, EPS‑accretive deal - Stock Titan
Ligand Pharmaceuticals (LGND) to Acquire XOMA Royalty for $39 pe - GuruFocus
Ligand Pharmaceuticals buying Xoma Royalty for $739 million - Yahoo Finance
Ligand Pharmaceuticals Inc Azioni (LGND) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.78%
3.01%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):